KRRO CLUSTER SEC Filing Analysis

Final — all horizons settled through T+60d ⚠ clustered

KRRO ▼ -3.48% at T+60d

LONG call ✗ call lost -3.48% · α vs SPY -15.17% · entry $11.48 → $11.08

Last close $10.59 (close Jun 8) · -7.75% from $11.48 entry

Entry anchored
Mar 9, 03:59 PM ET
via Databento tick

T+1d

+2.44%

call +2.44% · α +2.54%

$11.76

settled 3mo ago

T+5d

+7.23%

call +7.23% · α +8.14%

$12.31

settled 3mo ago

T+20d

+17.25%

call +17.25% · α +17.40%

$13.46

settled 2mo ago

T+60d

-3.48%

call -3.48% · α -15.17%

$11.08

settled 7d ago

Price Chart

Loading chart...

Executive Summary

Multiple insiders and institutional investors in Korro Bio (KRRO) collectively purchased over $20 million in open-market transactions within a single day, signaling strong confidence in the company. The buying was led by directors, executives, and major shareholders, with no offsetting sales or non-cash transactions diluting the signal.

Key Financial Metrics

Direction

buying

Total Value

$20.0M

Insiders

10

Actionable Insight

This level of coordinated insider buying — especially from both executives and sophisticated venture investors — is rare and typically precedes positive corporate developments. Traders should watch for upcoming catalysts such as clinical trial updates, partnerships, or financing that could unlock value.

Key Facts

Insiders and affiliated entities executed 14 open-market purchases totaling ~$20.0M in value on March 10, 2026.
Key buyers include Director Ali Behbahani (though his grant is non-cash), Scott Sandell, Forest Baskett, Edward Mathers, Paul Walker, Rick Yang, Carmen Chang, and Anthony Florence — all reputable investors or executives.
New Enterprise Associates 17, L.P., a major VC fund, also participated in the buying with over $5M in purchases.
All transactions were P (purchase) codes — no S (sales) or non-economic transactions like tax withholdings (F) or grants (A) were mixed in.
Total insider buying represents ~18% of the company's $111M market cap, a highly material signal for a biotech firm.

Financial Impact

$20.0 million in insider buying at $11.11/share, representing ~18% of market cap

market sentimentshareholder confidenceliquidity

Risk Factors

Biotech stocks are inherently volatile and sensitive to clinical trial outcomes.
The buying may be front-run if a near-term catalyst is already known internally.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

Document	Accession Number
CONTEXT: Insider Cluster Data (20 trades, 7d window)	cluster-KRRO-1773360938618

7 reports for KRRO

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for KRRO — sortable, filterable
	Type				Now
Jun 2, 2026 7d ago	Insider Cluster NEUTRAL ★ 3/10	$11.00 $11.08	▲ +0.73%	▲ +1.45%	$10.59 (−3.73%)
May 19, 2026 21d ago	8-K BULLISH ★ 6/10	$9.15 $10.01	▲ +9.40%	▲ +8.36%	$10.59 (+15.74%)
Apr 16, 2026 7w ago	DEFA14A NEUTRAL ★ 3/10	$13.47 $14.39	▲ +6.83%	▲ +5.62%	$10.59 (−21.38%)
Mar 23, 2026 11w ago	EFFECT NEUTRAL ★ 4/10	$11.27 $10.58	▼ −6.12%	▼ −5.77%	$10.59 (−6.03%)
Mar 13, 2026 12w ago	S-3 BEARISH ★ 7/10	$12.60 $12.31	▲ +2.30%	▲ +2.57%	$10.59 (+15.95%)
Mar 10, 2026 13w ago	Insider Cluster BULLISH ★ 8/10	$11.48 $11.76	▲ +2.44%	▲ +2.54%	$10.59 (−7.75%)
Mar 9, 2026 13w ago	Press Release NEUTRAL ★ 6/10	$12.30 $11.48	▼ −6.67%	▼ −6.48%	$10.59 (−13.90%)

US Market Status

Market Closed — Opens in 6h 57m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access